Faster cancer diagnosis by suspected cancer type

The share diagnosed or having cancer ruled out within 28 days, from breast and lung pathways to non-specific symptoms.

Embed this viewUpdated 1 Aug

Data access

Use the machine-readable JSON record or the flattened CSV download or the compact Markdown version.

Preview the latest 18 observations
SeriesPeriod or categoryValueUnit
Valuecancer - non-specific symptoms66.6259% diagnosed or ruled out within 28 days · 2026-05
ValueMissing or Invalid66.6667% diagnosed or ruled out within 28 days · 2026-05
Valueacute leukaemia68.75% diagnosed or ruled out within 28 days · 2026-05
Valueurological malignancies (excluding testicular)71.3324% diagnosed or ruled out within 28 days · 2026-05
Valuelower gastrointestinal cancer72.2428% diagnosed or ruled out within 28 days · 2026-05
Valuehaematological malignancies (excluding acute leukaemia)72.8205% diagnosed or ruled out within 28 days · 2026-05
Valuegynaecological cancer74.7044% diagnosed or ruled out within 28 days · 2026-05
Valueupper gastrointestinal cancer77.6574% diagnosed or ruled out within 28 days · 2026-05
Valuehead & neck cancer78.1595% diagnosed or ruled out within 28 days · 2026-05
Valuesarcoma82.6772% diagnosed or ruled out within 28 days · 2026-05
Valuelung cancer84.944% diagnosed or ruled out within 28 days · 2026-05
Valuetesticular cancer88.4211% diagnosed or ruled out within 28 days · 2026-05
Valueskin cancer88.8064% diagnosed or ruled out within 28 days · 2026-05
Valuechildren's cancer90.625% diagnosed or ruled out within 28 days · 2026-05
Valuebrain/central nervous system tumours91.1765% diagnosed or ruled out within 28 days · 2026-05
Valuebreast cancer92.0589% diagnosed or ruled out within 28 days · 2026-05
ValueExhibited (non-cancer) breast symptoms - cancer not initially suspected94.1028% diagnosed or ruled out within 28 days · 2026-05
Valueother cancer96.875% diagnosed or ruled out within 28 days · 2026-05

Methodology

Latest provider-level Faster Diagnosis Standard activity, aggregated across NHS London-region providers by suspected cancer type. Rates use within-standard activity divided by total eligible activity. The lowest-performing pathway is ranked first; small pathways can move sharply month to month and the latest data are provisional.

Provenance

Cadence
monthly
Engine
comparison

Keep going